Polymorphism of roxifiban

被引:11
作者
Maurin, MB
Vickery, RD
Rabel, SR
Rowe, SM
Everlof, JG
Nemeth, GA
Campbell, GC
Foris, CM
机构
[1] Dupont Merck Pharmaceut Co, Pharm R&D, Wilmington, DE 19880 USA
[2] Dupont Merck Pharmaceut Co, Chem & Phys Sci, Wilmington, DE 19880 USA
[3] DuPont Co Inc, Corp Ctr Analyt Sci, Wilmington, DE USA
[4] QS Pharma, Boothwyn, PA 19061 USA
[5] Bristol Myers Squibb Pharma, Wilmington, DE USA
[6] Alza Corp, Mt View, CA USA
关键词
roxifiban; polymorphism; thermodynamics; calorimetry; SS-NMR;
D O I
10.1002/jps.10078
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state carbon nuclear magnetic resonance. A slight difference between the two polymorphs was also detected by isothermal microcalorimetry. However, no differences were observed by differential scanning calorimetry, infrared, or Raman spectroscopy. Solubility studies as a function of temperature in a discriminating solvent system permitted characterization of the thermodynamics of the polymorphs. The enthalpy of solution at 25degreesC was 8.1 kcal/mol and 8.9 kcal/mol for Form I and Form II, respectively, and the thermodynamic transition point was 132degreesC. The data confirm that the polymorphs are enantiotropic. Form II is the thermodynamically stable crystal form over the practical range of drug substance storage and handling and dosage form processing and storage. However, Form I has been kinetically stable after storage for more than 36 months at 25degreesC/60% relative humidity with no conversion to Form II occurring. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:2599 / 2604
页数:6
相关论文
共 7 条
[1]  
Byrn S. R., 1982, SOLID STATE CHEM DRU
[2]  
GRANT DJ, SOLUBILITY BEHAV ORG
[3]   PHARMACEUTICAL APPLICATIONS OF POLYMORPHISM [J].
HALEBLIAN, J ;
MCCRONE, W .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1969, 58 (08) :911-+
[4]   Polymorph determination for the GP IIb/IIIa antagonist, roxifiban, using a combination of electron diffraction and synchrotron X-ray powder diffraction techniques [J].
Li, ZG ;
Harlow, RL ;
Foris, CM ;
Li, H ;
Ma, P ;
Vickery, RD ;
Maurin, MB ;
Toby, BH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (03) :297-301
[5]  
MAURIN MB, 1998, Patent No. 9857939
[6]  
MOUSA SA, 1996, CIRCULATION, V94, P5131
[7]   Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists [J].
Xue, CB ;
Wityak, J ;
Sielecki, TM ;
Pinto, DJ ;
Batt, DG ;
Cain, GA ;
Sworin, M ;
Rockwell, AL ;
Roderick, JJ ;
Wang, SG ;
Orwat, MJ ;
Frietze, WE ;
Bostrom, LL ;
Liu, J ;
Higley, CA ;
Rankin, FW ;
Tobin, AE ;
Emmett, G ;
Lalka, GK ;
Sze, JY ;
DiMeo, SV ;
Mousa, SA ;
Thoolen, MJ ;
Racanelli, AL ;
Hausner, EA ;
Reilly, TM ;
DeGrado, WF ;
Wexler, RR ;
Olson, RE .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (13) :2064-2084